198 related articles for article (PubMed ID: 1845126)
21. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
[TBL] [Abstract][Full Text] [Related]
22. HIV-1 soluble antigens induced CD8+ cytotoxic T-cell responses in an immunized individual.
Achour A; Moukrim Z; Picard O; Bizzini B; Burny A; Zagury D
Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):395-400. PubMed ID: 7580833
[TBL] [Abstract][Full Text] [Related]
23. Large-scale production and purification of a vaccinia recombinant-derived HIV-1 gp160 and analysis of its immunogenicity.
Barrett N; Mitterer A; Mundt W; Eibl J; Eibl M; Gallo RC; Moss B; Dorner F
AIDS Res Hum Retroviruses; 1989 Apr; 5(2):159-71. PubMed ID: 2713166
[TBL] [Abstract][Full Text] [Related]
24. Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gp160.
Hu SL; Klaniecki J; Dykers T; Sridhar P; Travis BM
AIDS Res Hum Retroviruses; 1991 Jul; 7(7):615-20. PubMed ID: 1768463
[TBL] [Abstract][Full Text] [Related]
25. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
[TBL] [Abstract][Full Text] [Related]
26. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
[TBL] [Abstract][Full Text] [Related]
27. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein.
Kaneko H; Bednarek I; Wierzbicki A; Kiszka I; Dmochowski M; Wasik TJ; Kaneko Y; Kozbor D
Virology; 2000 Feb; 267(1):8-16. PubMed ID: 10648178
[TBL] [Abstract][Full Text] [Related]
28. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.
Bruck C; Thiriart C; Fabry L; Francotte M; Pala P; Van Opstal O; Culp J; Rosenberg M; De Wilde M; Heidt P; Heeney J
Vaccine; 1994 Sep; 12(12):1141-8. PubMed ID: 7998425
[TBL] [Abstract][Full Text] [Related]
29. Immunization of chimpanzees with the HIV-1 glycoprotein gp160 induces long-lasting T-cell memory.
Mannhalter JW; Pum M; Wolf HM; Küpcü Z; Barrett N; Dorner F; Eder G; Eibl MM
AIDS Res Hum Retroviruses; 1991 May; 7(5):485-93. PubMed ID: 1714748
[TBL] [Abstract][Full Text] [Related]
30. Production in rabbits of high levels of anti-HIV-1 gp160 antibodies.
Relyveld E; Bizzini B
Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):389-93. PubMed ID: 7580832
[TBL] [Abstract][Full Text] [Related]
31. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner.
Gherardi MM; Ramirez JC; Rodríguez D; Rodríguez JR; Sano G; Zavala F; Esteban M
J Immunol; 1999 Jun; 162(11):6724-33. PubMed ID: 10352291
[TBL] [Abstract][Full Text] [Related]
32. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
Berman PW; Gregory TJ; Riddle L; Nakamura GR; Champe MA; Porter JP; Wurm FM; Hershberg RD; Cobb EK; Eichberg JW
Nature; 1990 Jun; 345(6276):622-5. PubMed ID: 2190095
[TBL] [Abstract][Full Text] [Related]
33. Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network.
Montefiori DC; Graham BS; Kliks S; Wright PF
J Clin Immunol; 1992 Nov; 12(6):429-39. PubMed ID: 1287035
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees.
Natuk RJ; Lubeck MD; Chanda PK; Chengalvala M; Wade MS; Murthy SC; Wilhelm J; Vernon SK; Dheer SK; Mizutani S
AIDS Res Hum Retroviruses; 1993 May; 9(5):395-404. PubMed ID: 8318268
[TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.
Belshe RB; Clements ML; Dolin R; Graham BS; McElrath J; Gorse GJ; Schwartz D; Keefer MC; Wright P; Corey L
J Infect Dis; 1993 Dec; 168(6):1387-95. PubMed ID: 8245523
[TBL] [Abstract][Full Text] [Related]
36. Induction of HIV type 1 neutralizing and env-CD4 blocking antibodies by immunization with genetically engineered HIV type 1-like particles containing unprocessed gp160 glycoproteins.
Rovinski B; Rodrigues L; Cao SX; Yao FL; McGuinness U; Sia C; Cates G; Zolla-Pazner S; Karwowska S; Matthews TJ
AIDS Res Hum Retroviruses; 1995 Oct; 11(10):1187-95. PubMed ID: 8573374
[TBL] [Abstract][Full Text] [Related]
37. Immunization of chimpanzees with recombinant gp160, but not infection with human immunodeficiency virus type 1, induces envelope-specific Th1 memory cells.
Mannhalter JW; Fischer MB; Wolf HM; Küpcü Z; Barrett N; Dorner F; Eder G; Eibl MM
J Infect Dis; 1995 Feb; 171(2):437-40. PubMed ID: 7844384
[TBL] [Abstract][Full Text] [Related]
38. Cross-neutralizing antibodies to HIV-1 in mice after immunization with gp160 iscoms. Dissection of the immune response.
Akerblom L; Nara P; Dunlop N; Morein B
AIDS Res Hum Retroviruses; 1991 Jul; 7(7):621-7. PubMed ID: 1768464
[TBL] [Abstract][Full Text] [Related]
39. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.
Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G
J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694
[TBL] [Abstract][Full Text] [Related]
40. Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.
Natuk RJ; Chanda PK; Lubeck MD; Davis AR; Wilhelm J; Hjorth R; Wade MS; Bhat BM; Mizutani S; Lee S
Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7777-81. PubMed ID: 1502197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
